Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

I-Mab IMAB NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
63/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

I-Mab (IMAB) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is bullish — 5 Buy.

IMAB Analyst Ratings

Buy
5
Ratings
5 Buy
Based on 5 analysts giving stock ratings to I-Mab in the past 3 months
Rating breakdown
Buy
5 100%
100%
Buy
5 analysts
0%
Hold
0 analysts
0%
Sell
0 analysts

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 BGNE
BGNE
BeiGene, Ltd.
$184.71
+0.49%
 ASND
ASND
Ascendis Pharma A/S
$249.84
+0.52%
 BPMC
BPMC
Blueprint Medicines Corporation
$129.46
+0.14%
 KRYS
KRYS
Krystal Biotech, Inc.
$270.00
+0.97%
 KYMR
KYMR
Kymera Therapeutics, Inc.
$89.87
+1.51%
 ERAS
ERAS
Erasca, Inc.
$17.85
+9.44%
 IMVT
IMVT
Immunovant, Inc.
$26.55
+5.69%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message